| Study | Exclusion reasons | Rmk | Reference |
|---|---|---|---|
| Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2018 | Overlapping between Vajda 2024a (1999 - 2023) and Vajda 2018 (1999 - 2016) based on the same register and for the almost same outcome (with or without elective termination) => Use of Vajda 2024a because accounting for more relevant confounders. | ||
| Vajda (Topiramate) (Controls unexposed, sick), 2018 | Overlapping between Vajda 2024a (1999 - 2023) and Vajda 2018 (1999 - 2016) based on the same register and for the almost same outcome (with or without elective termination) => Use of Vajda 2024a because accounting for more relevant confounders. | ||
| Coste (Topiramate) (Controls unexposed, sick) (Mixed indications), 2020 | EXCLUDED: this control group doesn't exist in the article (only in the report). Children with a diagnosis of brain malformation (ICD-10 codes Q00 to Q04 and Q05.0 to Q05.4) during their stay in the maternity unit are excluded. | ||
| He (Topiramate) (Controls exposed to Lamotrigine, sick), 2017 | repeat population groups, duplicate reports (most recent study included) | Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023. Patients who developed epilepsy during pregnancy or after delivery were not included. |
He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034 |
| He (Topiramate) (Controls unexposed, sick), 2017 | repeat population groups, duplicate reports (most recent study included) | Overlapping: He 2017 totally included in Li 2023, with a longer study period and more pregnancies => Use of Li 2023. Patients who developed epilepsy during pregnancy or after delivery were not included. |
He Epilepsy Behav 2017; 74:10-14 10.1016/j.yebeh.2017.05.034 |
| Hernandez-Diaz (Topiramate) (Epilepsy), 2024 | repeat population groups, duplicate reports (most recent study included) | EXCLUDED: Overlapping - Data totally included in Straub 2026, that included more pregnancies, longer follow up, more relevant period of exposure and non exposures. |
Hernandez-Diaz N Engl J Med 2024; 390:1069-1079 10.1056/NEJMoa2309359 |